ActRII and TGFβ Antagonists for Leukemia Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, such as chemotherapy and some immunotherapies, face challenges with high toxicity and limitations, including the emergence of resistant cancer cell variants and autoimmune adverse events, highlighting a need for effective therapies that enhance immune responses in cancer and infectious disease patients.
Innovation Solution
The use of ActRII antagonists and TGFβ antagonists, either alone or in combination, to treat cancer by decreasing tumor burden, increasing survival time, and synergistically enhancing antitumor activity, with the immune system playing a crucial role in their efficacy, potentially treating various cancers and infectious diseases, and boosting vaccine efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapy is used to treat cancer, then cancer cells are killed, but high toxicity and emergence of resistant cancer cell variants occur
Solution Approach 1:
The patent introduces TGFβ and ActRII as intermediary molecules that mediate the interaction between cancer cells and the immune system. By targeting these specific intermediaries, the therapy enhances immune-mediated cancer cell killing while avoiding the broad toxicity and resistance issues of conventional chemotherapy. The TGFβ receptor II (ActRII) serves as a critical intermediary that, when inhibited, allows enhanced T cell-mediated anti-tumor responses.
Solution Approach 2:
The patent changes the therapeutic parameter from direct cytotoxic chemotherapy to immunomodulation through TGFβ and ActRII inhibition. This parameter change shifts the mechanism of action from direct cell killing to enhancing the immune system's ability to recognize and eliminate cancer cells, thereby reducing toxicity and preventing resistance development.
2Reliability
If immunotherapy is used to enhance immune responses, then cancer cells are targeted by immune system, but autoimmune adverse events occur
Solution Approach 1:
The patent applies local quality by specifically targeting the TGFβ/ActRII pathway in the context of cancer immunity. Instead of broadly enhancing all immune responses (which causes autoimmune adverse events), the therapy locally modulates the TGFβ signaling pathway to enhance anti-tumor immunity while maintaining tolerance to self-antigens. This selective local enhancement explains the lack of autoimmune adverse events observed in clinical trials.
Solution Approach 2:
The patent uses monoclonal antibodies that copy the natural function of TGFβ by binding to and inhibiting its receptor (ActRII). This copying approach allows precise control over TGFβ signaling without the need for direct T cell activation, thereby enhancing anti-tumor immunity while avoiding the broad immune activation that leads to autoimmune adverse events.
3Reliability
If targeted therapy against oncoproteins is used, then tumor growth is inhibited, but cancer cells mutate and adapt to reduce dependency on the targeted pathway
Solution Approach 1:
The patent targets TGFβ and ActRII as key intermediaries in cancer cell survival and immune evasion. By inhibiting this intermediary pathway, the therapy disrupts multiple cancer cell processes simultaneously (apoptosis resistance, angiogenesis, immune evasion), making it harder for cancer cells to adapt and develop resistance compared to targeting single oncoproteins.
Solution Approach 2:
The TGFβ/ActRII pathway serves multiple functions in cancer biology, including promotion of cancer cell survival, induction of angiogenesis, and mediation of immune evasion. By targeting this universal pathway, the therapy simultaneously addresses multiple cancer cell adaptability mechanisms, reducing the likelihood of resistance development.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Disclosed herein are TGFβ antagonists and ActRII antagonists and methods for increasing immune responses and/or activity in patients in need thereof including, for example, cancer patients. For example, disclosed are methods of using a combination of ActRIIB-Fc and TGFβ antibody in the treatment of cancer, as well as in methods of inducing an immune response, treating or preventing immune exhaustion, inducing or potentiating an immune response against an antigen, vaccination against a pathogen or cancer in combination with pathogen or cancer antigens, and potentiating an immune response induced by a vaccine. Further included is anti-TGF-beta monotherapy in the same methods.